AVITA Medical, Inc. (RCEL) operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom.

It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.

The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin.

Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older.

AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. 

Shares have formed a bullish cup and handle following its latest earnings report. On February 23rd, Avita Medical (RCEL) reported a Quarter December 2022 loss of $0.21 per share on revenue of $9.5 million. The consensus estimate was a loss of $0.32 per share on revenue of $7.9 million. Revenue grew 36.3% on a year-over-year basis. Higher share prices are expected.

Entry Point: $16.60

Trading Range: $4.4102 to $16.89

Stop Loss: $15.70

Target Price: $18.25